Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 93.17 EUR 2.53% Market Closed
Market Cap: 116.8B EUR
Have any thoughts about
Sanofi SA?
Write Note

Sanofi SA
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sanofi SA
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Sanofi SA
PAR:SAN
Other Long-Term Assets
€7.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Other Long-Term Assets
€348.6m
CAGR 3-Years
14%
CAGR 5-Years
15%
CAGR 10-Years
5%
Vetoquinol SA
PAR:VETO
Other Long-Term Assets
€10m
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
4%
Virbac SA
PAR:VIRP
Other Long-Term Assets
€29m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Other Long-Term Assets
€18.9m
CAGR 3-Years
-20%
CAGR 5-Years
-13%
CAGR 10-Years
-8%
Medincell SA
PAR:MEDCL
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sanofi SA
Glance View

Market Cap
116.6B EUR
Industry
Pharmaceuticals

Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the evolving healthcare demands of a global population. For investors, Sanofi represents a compelling opportunity due to its strong commitment to research and development, which accounted for approximately 16% of its revenue last year. The company’s strategic initiatives focus on enhancing its product line while also forming strategic alliances and partnerships to foster innovation. Furthermore, Sanofi’s solid financial performance, characterized by consistent revenue growth and healthy dividend payouts, showcases its operational efficiency and reliability. As the healthcare landscape continues to shift, Sanofi's agility in adapting to new challenges, coupled with its focus on science and patient needs, sets it apart as a strong contender in the biopharmaceutical industry, providing investors with a platform for sustainable long-term growth.

SAN Intrinsic Value
109.65 EUR
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Sanofi SA's Other Long-Term Assets?
Other Long-Term Assets
7.8B EUR

Based on the financial report for Sep 30, 2024, Sanofi SA's Other Long-Term Assets amounts to 7.8B EUR.

Back to Top